



Our key strengths are:

Source

❖ Translational research

Partnership agreements with an increasing number of academic centers of excellence. Our aim is to identify the best academic projects and develop them into negotiable assets over 3 to 5 years. *"We select projects, not start-ups!"*



❖ Venture

The combined experience of the team opens up a rich European network of opportunities especially through specialist conferences, contacts with past co-investors, start-ups and partnered institutes.



- The fund's primary objective is to invest in early stage European life science companies with a specific focus towards orphan diseases.
- 50 % of the fund will be dedicated directly or indirectly to orphan disease indications.
- Projects will be selected at all stages of maturity for their ability to fit with Kurma investment philosophy: high innovation, strict control of operations, limited burn rate, 3 to 5 years exit and the potential to make a significant financial return to the fund.
- Key investors in Kurma Biofund II are **GSK**, **Caisse des Dépôts**, **NEA** and **Idinvest**.



NEA®

idinvest
PARTNERS

rare 2013

Les rencontres Eurobiomed des maladies rares

